The GLP‐1 and GIP receptor agonists, along with the triple agonist of GIP, GLP‐1, and glucagon receptor, showed good efficacy in promoting weight loss in obese patients with type 2 diabetes mellitus. This evidence concerns the gene GCG and type 2 diabetes mellitus.